S. 5459
118th Congress
Senate
Biosimilars Access and Affordability Act
Official title: A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Everywhere this bill has been
2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 9, 2024
Read twice and referred to the Committee on Finance.
Dec 9, 2024
Introduced in Senate
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Latest action
Read twice and referred to the Committee on Finance.
Bill text
1 version
- Introduced in Senate Formatted Text PDF Formatted XML
Committees of jurisdiction
1
Lobbying activity
8
- AVENUE SOLUTIONS
- GSK (FKA GLAXOSMITHKLINE INC.)
- COVINGTON & BURLING LLP
- PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
- GSK (FKA GLAXOSMITHKLINE INC.)
- PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Bodies those filers lobbied
- SENATE
- HOUSE OF REPRESENTATIVES
- Centers For Medicare and Medicaid Services (CMS)
- Health & Human Services, Dept of (HHS)
- Patent & Trademark Office (PTO)
- Food & Drug Administration (FDA)
- Office of Management & Budget (OMB)
- U.S. Trade Representative (USTR)
Cite this page
U.S. Congress. (2026). S. 5459: Biosimilars Access and Affordability Act. 118th Congress. Open America. https://openamerica.io/bill/118-S-5459/
"S. 5459: Biosimilars Access and Affordability Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-5459/.
S. 5459, 118th Cong. (2026), https://openamerica.io/bill/118-S-5459/.
[S. 5459: Biosimilars Access and Affordability Act](https://openamerica.io/bill/118-S-5459/)